<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04751188</url>
  </required_header>
  <id_info>
    <org_study_id>R-2020-2101-031</org_study_id>
    <nct_id>NCT04751188</nct_id>
  </id_info>
  <brief_title>A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis</brief_title>
  <official_title>Safety and Efficacy of Bezafibrate Plus Ursodesoxicolic Acid in Patients With Primary Biliary Cholangitis Without Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Mexicano del Seguro Social</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 40% of patients with PBC have an inadequate response to standard treatment with&#xD;
      Ursodeoxycholic Acid (UDCA), those patients represent the group in need for additional&#xD;
      therapies, having increased risk of disease progression and decreased survival free of liver&#xD;
      transplantation.&#xD;
&#xD;
      The main objective of the study is to evaluate safety and efficacy of bezafibrate plus&#xD;
      ursodesoxicolic acid in patients with PBC and inadequate response to UDCA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical response</measure>
    <time_frame>6 months</time_frame>
    <description>Biochemical response is defined as the reduction of alkaline phosphatase lower than 1.5 times the upper normal limit, reduction of aspartate transaminase lower than 1.5 times the upper normal limit and bilirubin lower than 1 mg/dl.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline and 6 months later</time_frame>
    <description>Evaluation of quality of life with the Primary Biliary Cholangitis 40 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus intensity</measure>
    <time_frame>Baseline and 6 months later</time_frame>
    <description>Evaluation made by the use of visual analogue scales.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">11</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Bezafibrate and Ursodeoxycholic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bezafibrate 200 mg every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Ursodeoxycholic acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bezafibrate 200 MG Oral Tablet</intervention_name>
    <description>Bezafibrate one tablet every 12 hours for six months.</description>
    <arm_group_label>Bezafibrate and Ursodeoxycholic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo one tablet every 12 hours for six months.</description>
    <arm_group_label>Placebo and Ursodeoxycholic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic Acid</intervention_name>
    <description>At a dose of 13 to 15 mg per Kg per day.</description>
    <arm_group_label>Bezafibrate and Ursodeoxycholic acid</arm_group_label>
    <arm_group_label>Placebo and Ursodeoxycholic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PBC diagnosis (consistent with American Association for the Study of Liver Disease&#xD;
             [AASLD]:&#xD;
&#xD;
               -  History of elevated alkaline phosphatase levels.&#xD;
&#xD;
               -  Anti-mitochondrial antibodies positivity&#xD;
&#xD;
               -  Histopathologic evidence of nonsuppurative cholangitis and destruction of small&#xD;
                  or medium- sized bile ducts.&#xD;
&#xD;
          -  Use of ursodeoxycholic acid (UDCA) for at least 12 months at enrollment at a&#xD;
             therapeutic dose (13 to 15 mg per Kg per day).&#xD;
&#xD;
          -  Evidence of a suboptimal biochemical response to UDCA, defined by the presence of one&#xD;
             of the Paris II criteria.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Age â‰¥ 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatic decompensation (ascitis, variceal upper gastrointestinal bleeding, hepatic&#xD;
             encephalopathy).&#xD;
&#xD;
          -  Coexistence autoimmune hepatitis.&#xD;
&#xD;
          -  Bilirrubin &gt;3mg/dl.&#xD;
&#xD;
          -  For females, pregnancy or breast-feeding.&#xD;
&#xD;
          -  Hepatocellular carcinoma.&#xD;
&#xD;
          -  History or presence of spontaneous bacterial peritonitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Mexicano de Seguro Social</name>
      <address>
        <city>Puebla</city>
        <zip>72000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Mexicano del Seguro Social</investigator_affiliation>
    <investigator_full_name>Jocelyn Serrano Casas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ursodeoxycholic acid</keyword>
  <keyword>Bezafibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
    <mesh_term>Bezafibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

